Latest News for Adverum Biotechnologies Stock (NASDAQ:ADVM)

Thursday, December 07, 2023

Adverum Biotechnologies To Present LUNA Preliminary Efficacy And Safety Data At The 47th Annual Meeting Of The Macula Society
Benzinga Newsdesk - 19 hours ago

Thursday, November 09, 2023

Adverum Biotechnologies Q3 EPS $(0.33) Misses $(0.32) Estimate
Benzinga Newsdesk - Nov 9, 2023, 5:26PM

Tuesday, November 07, 2023

Board Member at Adverum Biotechnologies Acquires Company Stock Options Worth 80,000 Shares
Benzinga Insights - Nov 7, 2023, 10:00AM

Monday, November 06, 2023

Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?
Vandana Singh - Nov 6, 2023, 1:08PM
Adverum Biotechnologies Announces 3-Year Efficacy And Safety Results From The OPTIC Extension Study In Patients With Wet AMD At AAO 2023
Benzinga Newsdesk - Nov 6, 2023, 1:28AM

Thursday, November 02, 2023

Adverum Biotechnologies shares are trading higher after Mizuho initiated coverage on the stock with a Buy rating and announced a $2 price target.
Benzinga Newsdesk - Nov 2, 2023, 12:57PM
Mizuho Initiates Coverage On Adverum Biotechnologies with Buy Rating, Announces Price Target of $2
Benzinga Newsdesk - Nov 2, 2023, 5:52AM

Tuesday, September 26, 2023

Adverum Biotechnologies Reports Aflibercept Protein Level Data From LUNA Phase 2 Trial; Says Ixo-vec Has Been Well Tolerated With Favorable Preliminary Safety Profile
Benzinga Newsdesk - Sep 26, 2023, 4:07PM

Tuesday, September 05, 2023

Truist Securities Reiterates Buy on Adverum Biotechnologies, Maintains $6 Price Target
Benzinga Newsdesk - Sep 5, 2023, 10:03AM

Friday, August 11, 2023

Chardan Capital Upgrades Adverum Biotechnologies to Buy, Raises Price Target to $4
Benzinga Newsdesk - Aug 11, 2023, 1:05PM

Thursday, August 10, 2023

Adverum Biotechnologies Completes Enrollment Of Phase 2 LUNA Trial In Wet AMD
Happy Mohamed - Aug 10, 2023, 5:11PM
Adverum Biotechnologies Q2 EPS $(0.31) Up From $(0.44) YoY
Benzinga Newsdesk - Aug 10, 2023, 5:11PM

Thursday, June 22, 2023

Short Volatility Alert: Adverum Biotechnologies
Christopher Sappo - Jun 22, 2023, 12:25PM

Wednesday, June 14, 2023

On June 13, Adverum Biotechnologies Inc Received Written From Nasdaq Stating That Co Has Regained Compliance With Minimum Bid Price Requirement
Benzinga Newsdesk - Jun 14, 2023, 4:04PM
Adverum Biotechnologies Board Member Awarded $79K Worth of Stock Options
Benzinga Insights - Jun 14, 2023, 11:03AM
Adverum Biotechnologies Director Awarded $60K Worth of Stock Options
Benzinga Insights - Jun 14, 2023, 11:02AM
Adverum Biotechnologies Board Member Awarded $60K Worth of Stock Options
Benzinga Insights - Jun 14, 2023, 11:01AM

Monday, June 12, 2023

Over $14M Bet On Diversified Healthcare Trust? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Lisa Levin - Jun 12, 2023, 9:25AM

Thursday, May 25, 2023

12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights - May 25, 2023, 1:31PM

Thursday, May 18, 2023

Adverum Biotechnologies Introduces An Intravitreal Gene Therapy Program For Geographic Atrophy And Presents Data On Its Ocular Gene Therapy Platform
Happy Mohamed - May 18, 2023, 9:10AM
Adverum Biotechnologies Presents Nonclinical Data In Support Of Ixo-vec's Phase 2 Clinical Development At ASGCT 2023 Annual Meeting
Happy Mohamed - May 18, 2023, 9:09AM

Sunday, April 23, 2023

Adverum Biotechnologies Presented Nonclinical Data Sunday at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec
Charles Gross - Apr 23, 2023, 7:29PM

Tuesday, April 18, 2023

Adverum Biotechnologies Granted Innovative Licensing And Access Pathway Designation In UK For Ixo-vec For Treatment Of Wet AMD
Benzinga Newsdesk - Apr 18, 2023, 8:14AM

Monday, April 17, 2023

Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration Of Ixoberogene Soroparvovec At The 2023 ARVO Annual Meeting
Happy Mohamed - Apr 17, 2023, 4:07PM

Thursday, March 30, 2023

Adverum Biotechnologies Q4 EPS $(0.33) Beats $(0.36) Estimate
Michael Horton - Mar 30, 2023, 4:24PM

Tuesday, March 07, 2023

Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Benzinga Insights - Mar 7, 2023, 10:00AM
Ladenburg Thalmann Initiates Coverage On Adverum Biotechnologies with Buy Rating, Announces Price Target of $2
Benzinga Newsdesk - Mar 7, 2023, 8:39AM

Tuesday, December 27, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Dec 27, 2022, 11:31AM

Tuesday, December 20, 2022

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Dec 20, 2022, 11:55AM

Friday, December 16, 2022

Stocks That Hit 52-Week Lows On Friday
Benzinga Insights - Dec 16, 2022, 12:39PM

Monday, November 28, 2022

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Nov 28, 2022, 4:32PM

Friday, November 25, 2022

Adverum Biotechnologies On Nov. 18 Received Nasdaq Letter Notifying Co. Bid Price Had Closed Below $1/Share For Last 30 Days
Benzinga Newsdesk - Nov 25, 2022, 6:08AM

Friday, November 11, 2022

Chardan Capital Maintains Neutral on Adverum Biotechnologies, Lowers Price Target to $2
Benzinga Newsdesk - Nov 11, 2022, 8:23AM
RBC Capital Maintains Sector Perform on Adverum Biotechnologies, Lowers Price Target to $3
Benzinga Newsdesk - Nov 11, 2022, 8:06AM

Thursday, November 10, 2022

Adverum Biotechnologies Q3 EPS $(0.40) Down From $(0.39) YoY
Benzinga Newsdesk - Nov 10, 2022, 4:46PM

Friday, November 04, 2022

Adverum Biotechnologies Presents End Of Study Results From The OPTIC Trial In Wet AMD Including Two-Year Outcomes Following A Single Intravitreal Injection Of Ixo-vec
Benzinga Newsdesk - Nov 4, 2022, 12:10PM

Wednesday, October 26, 2022

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Oct 26, 2022, 8:06AM

Wednesday, September 14, 2022

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary
Ragothaman Srinivasan - Sep 14, 2022, 5:29PM
Adverum Commences Mid-Stage Chronic Eye Disorder Candidate Study
Ragothaman Srinivasan - Sep 14, 2022, 2:28PM
Adverum Biotechnologies Announces First Subject Dosed With Ixo-vec In Phase 2 LUNA Trial For Treatment Of Wet Age-Related Macular Degeneration
Bill Haddad - Sep 14, 2022, 8:07AM

Friday, August 26, 2022

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Aug 26, 2022, 8:32AM

Friday, August 12, 2022

Chardan Capital Maintains Neutral on Adverum Biotechnologies, Lowers Price Target to $2.5
Benzinga Newsdesk - Aug 12, 2022, 9:04AM

Thursday, August 11, 2022

Adverum Biotechnologies Q2 EPS $(0.44) Up From $(0.45) YoY
Benzinga Newsdesk - Aug 11, 2022, 4:57PM

Monday, July 18, 2022

Why Bank Stocks Traded Sharply Higher; Here Are 65 Biggest Movers From Friday
Lisa Levin - Jul 18, 2022, 5:43AM

Friday, July 15, 2022

Citigroup, Bank of America And 48 Stocks Moving In Friday's Mid-Day Session
Lisa Levin - Jul 15, 2022, 12:11PM
Adverum Biotechnologies shares are trading lower after the company announced new data from the OPTIC study during the American Society of Retina Specialists 2022 Annual Meeting.
Michael Horton - Jul 15, 2022, 12:06PM
Adverum Posts New Data From Wet AMD Gene Therapy Trial
Vandana Singh - Jul 15, 2022, 9:52AM
The Daily Biotech Pulse: FDA Signs Off Cancer Therapy Trials For NexImmune, Omega Therapeutics, Endo To Develop Rare Hereditary Skin Disease Candidate
Vandana Singh - Jul 15, 2022, 9:03AM
Adverum Biotechnologies Presents Best-Corrected Visual Acuity And Central Subfield Thickness Analyses After Single IVT Injection Of ADVM-022 (Ixo-vec) In OPTIC Study In Wet AMD
Benzinga Newsdesk - Jul 15, 2022, 8:57AM

Thursday, July 07, 2022

Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
Benzinga Insights - Jul 7, 2022, 10:04AM

Open1.020	Close-
Vol / Avg.180.215K / 246.666K	Mkt Cap98.006M
Day Range0.970 - 1.040	52 Wk Range0.535 - 2.340

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Adverum Biotechnologies Stock (NASDAQ:ADVM)

Thursday, December 07, 2023

Thursday, November 09, 2023

Tuesday, November 07, 2023

Monday, November 06, 2023

Thursday, November 02, 2023

Tuesday, September 26, 2023

Tuesday, September 05, 2023

Friday, August 11, 2023

Thursday, August 10, 2023

Thursday, June 22, 2023

Wednesday, June 14, 2023

Monday, June 12, 2023

Thursday, May 25, 2023

Thursday, May 18, 2023

Sunday, April 23, 2023

Tuesday, April 18, 2023

Monday, April 17, 2023

Thursday, March 30, 2023

Tuesday, March 07, 2023

Tuesday, December 27, 2022

Tuesday, December 20, 2022

Friday, December 16, 2022

Monday, November 28, 2022

Friday, November 25, 2022

Friday, November 11, 2022

Thursday, November 10, 2022

Friday, November 04, 2022

Wednesday, October 26, 2022

Wednesday, September 14, 2022

Friday, August 26, 2022

Friday, August 12, 2022

Thursday, August 11, 2022

Monday, July 18, 2022

Friday, July 15, 2022

Thursday, July 07, 2022